ID

15860

Beschreibung

Micro RNAs to Predict Response to Androgen Deprivation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02366494

Link

https://clinicaltrials.gov/show/NCT02366494

Stichworte

  1. 16.06.16 16.06.16 -
Hochgeladen am

16. Juni 2016

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


    Keine Kommentare

    Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

    Eligibility Prostate Cancer NCT02366494

    Eligibility Prostate Cancer NCT02366494

    Inclusion Criteria
    Beschreibung

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    histologically proven prostate cancer.
    Beschreibung

    prostate cancer

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0600139
    testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.
    Beschreibung

    Testosterone measurement | Hormone Therapy

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0523912
    UMLS CUI [2]
    C0279025
    history/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
    Beschreibung

    Physical Examination | Prostate carcinoma | TNM clinical staging

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0031809
    UMLS CUI [2]
    C0600139
    UMLS CUI [3]
    C3258246
    ct scan of abdomen and pelvis with iv contrast and bone scan should be performed within 8 weeks prior to registration.
    Beschreibung

    CT with intravenous contrast Abdomen | CT with intravenous contrast Pelvis | Radioisotope scan of bone

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0202653
    UMLS CUI [1,2]
    C0000726
    UMLS CUI [2,1]
    C0202653
    UMLS CUI [2,2]
    C0030797
    UMLS CUI [3]
    C0203668
    ecog performance status 0-2.
    Beschreibung

    ECOG performance status

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C1520224
    age ≥ 18.
    Beschreibung

    Age

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).
    Beschreibung

    Informed Consent | Blood specimen Requirement | BLOOD BANKING | Genetic testing

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    UMLS CUI [2,1]
    C0178913
    UMLS CUI [2,2]
    C1514873
    UMLS CUI [3]
    C0200495
    UMLS CUI [4]
    C0679560
    Exclusion Criteria
    Beschreibung

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    received hormonal therapy less than 6 months prior to registration.
    Beschreibung

    Hormone Therapy

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0279025
    history of active secondary malignancy.
    Beschreibung

    Secondary Malignant Neoplasm

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C3266877
    decline hormone therapy for prostate cancer.
    Beschreibung

    Prostate carcinoma | Hormone Therapy Refused

    Datentyp

    boolean

    Alias
    UMLS CUI [1]
    C0600139
    UMLS CUI [2,1]
    C0279025
    UMLS CUI [2,2]
    C1705116
    current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.
    Beschreibung

    Therapeutic procedure 5-alpha Reductase Inhibitors

    Datentyp

    boolean

    Alias
    UMLS CUI [1,1]
    C0087111
    UMLS CUI [1,2]
    C2936788

    Ähnliche Modelle

    Eligibility Prostate Cancer NCT02366494

    Name
    Typ
    Description | Question | Decode (Coded Value)
    Datentyp
    Alias
    Item Group
    C1512693 (UMLS CUI)
    prostate cancer
    Item
    histologically proven prostate cancer.
    boolean
    C0600139 (UMLS CUI [1])
    Testosterone measurement | Hormone Therapy
    Item
    testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.
    boolean
    C0523912 (UMLS CUI [1])
    C0279025 (UMLS CUI [2])
    Physical Examination | Prostate carcinoma | TNM clinical staging
    Item
    history/physical examination including a detailed description of the stage of prostate cancer within 8 weeks prior to registration.
    boolean
    C0031809 (UMLS CUI [1])
    C0600139 (UMLS CUI [2])
    C3258246 (UMLS CUI [3])
    CT with intravenous contrast Abdomen | CT with intravenous contrast Pelvis | Radioisotope scan of bone
    Item
    ct scan of abdomen and pelvis with iv contrast and bone scan should be performed within 8 weeks prior to registration.
    boolean
    C0202653 (UMLS CUI [1,1])
    C0000726 (UMLS CUI [1,2])
    C0202653 (UMLS CUI [2,1])
    C0030797 (UMLS CUI [2,2])
    C0203668 (UMLS CUI [3])
    ECOG performance status
    Item
    ecog performance status 0-2.
    boolean
    C1520224 (UMLS CUI [1])
    Age
    Item
    age ≥ 18.
    boolean
    C0001779 (UMLS CUI [1])
    Informed Consent | Blood specimen Requirement | BLOOD BANKING | Genetic testing
    Item
    patients must provide study-specific informed consent prior to study entry for this project and mandatory blood specimen for banking for future studies (future studies may include genetic testing).
    boolean
    C0021430 (UMLS CUI [1])
    C0178913 (UMLS CUI [2,1])
    C1514873 (UMLS CUI [2,2])
    C0200495 (UMLS CUI [3])
    C0679560 (UMLS CUI [4])
    Item Group
    C0680251 (UMLS CUI)
    Hormone Therapy
    Item
    received hormonal therapy less than 6 months prior to registration.
    boolean
    C0279025 (UMLS CUI [1])
    Secondary Malignant Neoplasm
    Item
    history of active secondary malignancy.
    boolean
    C3266877 (UMLS CUI [1])
    Prostate carcinoma | Hormone Therapy Refused
    Item
    decline hormone therapy for prostate cancer.
    boolean
    C0600139 (UMLS CUI [1])
    C0279025 (UMLS CUI [2,1])
    C1705116 (UMLS CUI [2,2])
    Therapeutic procedure 5-alpha Reductase Inhibitors
    Item
    current or previous treatment with 5-alpha reductase inhibitors within 6 months prior to enrollment.
    boolean
    C0087111 (UMLS CUI [1,1])
    C2936788 (UMLS CUI [1,2])

    Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

    Zum Video